NYSEMKT:IBIO iBio (IBIO) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free IBIO Stock Alerts $1.97 -0.06 (-2.96%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$1.95▼$2.1450-Day Range$1.06▼$4.0652-Week Range N/AVolume174,321 shsAverage Volume113,212 shsMarket Capitalization$6.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get iBio alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About iBio Stock (NYSEMKT:IBIO)iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesMarch 28, 2024 | msn.comiBio, Mesoblast, Kodiak Sciences among healthcare moversMarch 27, 2024 | msn.comMicro-Cap Stock iBio Doubles On Wednesday - Here's WhyMay 3, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...March 27, 2024 | proactiveinvestors.comiBio partners with AstralBio to develop obesity treatments using AI-driven platformMarch 27, 2024 | marketwatch.comiBio Shares Double After Collaboration Agreement With AstralBioMarch 27, 2024 | investorplace.comWhy Is iBio (IBIO) Stock Up 125% Today?March 27, 2024 | msn.comMega Millions winning numbers for enormous $1.1 billion jackpot on March 26March 27, 2024 | msn.comRon DeSantis signs bill banning social media for kids under 14 in FloridaMay 3, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 27, 2024 | globenewswire.comiBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic DiseasesMarch 26, 2024 | globenewswire.comiBio Announces $15.0 Million Private PlacementFebruary 26, 2024 | marketwatch.comiBio Sells Preclinical PD-1 Antagonist Antibody Program to OtsukaFebruary 26, 2024 | globenewswire.comiBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to OtsukaFebruary 22, 2024 | money.usnews.comiBio IncFebruary 13, 2024 | msn.comHow to capture screenshots on your Mac: A step-by-step guideFebruary 12, 2024 | msn.comTrain hits, kills person who trespassed on tracks in HaywardFebruary 12, 2024 | msn.comUsher's Wife Responds To Alicia Keys Super Bowl DramaJanuary 16, 2024 | finance.yahoo.comiBio Announces Participation in 23rd Annual PepTalk ConferenceDecember 26, 2023 | finance.yahoo.comiBio Amends and Extends Maturity of Credit AgreementDecember 8, 2023 | benzinga.comLooking Into iBio's Recent Short InterestDecember 5, 2023 | marketwatch.comIBio Shares Drop 43% After Public OfferingDecember 5, 2023 | msn.comiBio prices 2.25M shares at $2.00 in public offeringDecember 5, 2023 | markets.businessinsider.comIBio Prices Public Offering Of 2.25 Mln Shares At $2/shrDecember 5, 2023 | finance.yahoo.comiBio, Inc. Announces Pricing of $4.5 Million Public OfferingNovember 28, 2023 | benzinga.comiBio Stock (AMEX:IBIO) Dividends: History, Yield and DatesNovember 28, 2023 | finanznachrichten.deiBio, Inc.: iBio Announces Reverse Stock SplitNovember 28, 2023 | msn.comWhy iBio Stock Is Plunging SharplySee More Headlines Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/03/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEMKT:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone(302) 355-0650Fax302-356-1173Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-41,546.00% Return on Equity-150.59% Return on Assets-52.83% Debt Debt-to-Equity Ratio0.04 Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$50,000.00 Price / Sales141.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book0.77Miscellaneous Outstanding Shares3,484,000Free Float3,445,000Market Cap$7.07 million OptionableN/A Beta-3.51 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 53)Ph.D., CEO & Chief Scientific Officer Comp: $577.31kMr. Felipe Duran (Age 44)Chief Financial Officer Comp: $1.07MStephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.General CounselMr. Robert B. Kay (Age 84)Interim Secretary & Interim Treasurer Comp: $92.69kKey CompetitorsTherapix BiosciencesOTCMKTS:TRPXYBioRestorative TherapiesOTCMKTS:BRTXEiger BioPharmaceuticalsNASDAQ:EIGRPHAXIAM TherapeuticsNASDAQ:PHXMTraws PharmaNASDAQ:TRAWView All CompetitorsInsidersMartin BrennerSold 210 sharesTotal: $1,302.00 ($6.20/share)Martin BrennerSold 250 sharesTotal: $1,550.00 ($6.20/share)Martin BrennerSold 225 sharesTotal: $2,295.00 ($10.20/share)Martin BrennerSold 2,351 sharesTotal: $27,741.80 ($11.80/share)Martin BrennerSold 209 sharesTotal: $2,842.40 ($13.60/share)View All Insider Transactions IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed in 2024? iBio's stock was trading at $1.37 at the start of the year. Since then, IBIO stock has increased by 43.8% and is now trading at $1.97. View the best growth stocks for 2024 here. How were iBio's earnings last quarter? iBio, Inc. (NYSEMKT:IBIO) released its quarterly earnings results on Monday, November, 15th. The company reported ($20.00) earnings per share for the quarter, topping the consensus estimate of ($25.00) by $5.00. The company earned $0.21 million during the quarter. When did iBio's stock split? iBio shares reverse split before market open on Wednesday, November 29th 2023. The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEMKT:IBIO) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
